Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences Track

Tracer kinetic analysis of the SV2A ligand 11C-UCBA as a PET marker for synaptic density in humans

Mark Lubberink, Lieuwe Appel, Johannes Daging, Karolina Lindskog, Torsten Danfors, Elna-Marie Larsson, Eva Kumlien and Gunnar Antoni
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 631;
Mark Lubberink
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lieuwe Appel
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Daging
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karolina Lindskog
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Torsten Danfors
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elna-Marie Larsson
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Kumlien
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunnar Antoni
1Uppsala University Uppsala Sweden
2Uppsala University Uppsala Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

631

Objectives: Quantitative imaging of the synaptic vesicle glycoprotein 2A (SV2A) with PET can be used as a measure of synaptic density in the human brain (Finnema et al, Science Tr Med 2016), changes of which occur in many neurodegenerative diseases. 11C-UCBA has previously been validated as an SV2A tracer in pigs (Estrada et al, Nucl Med Biol 2016), showing dose-dependent blocking and reversible binding. The aim of the present work was to evaluate tracer kinetic models and simplified methods for quantification of synaptic density using 11C-UCBA in humans.

Methods: Eight subjects (6 epilepsy patients, 2 controls) underwent 90 min PET scans starting with injection of 5 MBq/kg 11C-UCBA on a time-of-flight integrated PET-MR scanner (Signa PET-MR, GE Healthcare). Arterial blood was withdrawn for measurements of whole blood and plasma concentrations and metabolite analysis. Images were reconstructed using zero-echo-time MR-based attenuation correction, accounting for bone attenuation. A probabilistic VOI template was defined on a T1-MRI image, acquired during the PET scan, and transferred to the dynamic PET images. A centrum semiovale VOI was drawn as potential reference tissue. Data were analysed using single-tissue (1T2k), two-tissue irreversible (2T3k) and reversible (2T4k) models, as well as the simplified reference tissue model (SRTM) and plasma- and reference-Logan methods, resulting in total distribution volume (VT) and binding potential (BPND) values, with binding potential both estimated directly and as distribution volume ratio to centrum semiovale (DVR). The optimal compartment model was determined using the Akaike information criterion (AIC). Standardized uptake value ratios (SUVR) at various time points were compared to modelling outcomes using regression analysis.

Results: Plasma and brain kinetics of 11C-UCBA were slow, with peak activity in brain at 70-80 min. Parent fraction was approximately 50% at 90 min. Plasma-input data were best described using the 2T4k model, but this could often not provide robust VT or BPND values. Mean plasma-Logan VT was 24±17. Plasma-Logan DVR using centrum semiovale as reference tissue correlated well with 2T4k DVR (R2 0.94) for those regions where robust DVR values could be determined. Reference-Logan DVR showed good correlation with plasma-Logan DVR (R2 0.72). Plasma-Logan DVR-1 and SUVR-1 images are shown in Figure 1. SUVR for the 40-60 and 70-90 min intervals correlated well with reference-Logan DVR (R2 0.92 and 0.98).

Conclusion: Slow kinetics of 11C-UCBA resulted in poor robustness of outcome parameters of reversible compartment models. However, reference-Logan DVR correlated well with plasma-Logan DVR. SUVR at 70-90 min p.i. correlated well with DVR and may be used as a simplified measure of synaptic density using 11C-UCBA. Research Support: Uppsala County Council

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 58, Issue supplement 1
May 1, 2017
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tracer kinetic analysis of the SV2A ligand 11C-UCBA as a PET marker for synaptic density in humans
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Tracer kinetic analysis of the SV2A ligand 11C-UCBA as a PET marker for synaptic density in humans
Mark Lubberink, Lieuwe Appel, Johannes Daging, Karolina Lindskog, Torsten Danfors, Elna-Marie Larsson, Eva Kumlien, Gunnar Antoni
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 631;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tracer kinetic analysis of the SV2A ligand 11C-UCBA as a PET marker for synaptic density in humans
Mark Lubberink, Lieuwe Appel, Johannes Daging, Karolina Lindskog, Torsten Danfors, Elna-Marie Larsson, Eva Kumlien, Gunnar Antoni
Journal of Nuclear Medicine May 2017, 58 (supplement 1) 631;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences Track

  • Impact of cognitive reserve in frontotemporal dementia illustrated by FDG-PET.
  • Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with 18F-FEOBV
  • Kinetic evaluation of [18F]MOZAT PET imaging in humans.
Show more Neurosciences Track

Novel Clinical Applications in Tauopathy and Epilepsy

  • INITIAL CLINICAL PET STUDIES WITH THE NOVEL TAU AGENT 18-F PI-2620 IN ALZHEIMER'S DISEASE AND CONTROLS
  • Differential sensitivity of CSF markers of p-tau and t-tau to in vivo tau deposition assessed with [18F]-AV-1451 in typical and atypical Alzheimer’s disease
  • Reduced SV2A binding in the seizure onset zone in temporal lobe epilepsy patients - A PET study with 11C-UCB-J
Show more Novel Clinical Applications in Tauopathy and Epilepsy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire